Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

FLCCC Alliance Adds Ivermectin Alternative to I-MASK+ Prevention & Early Treatment Protocol


WLT has talked about ivermectin a lot and provided you the real information about this safe, effective Nobel Prize-winning medication.

Ivermectin has been FDA-approved since 1996 and is on the WHO list of essential medicines (page 6).

Remember this disclaimer:

I am not a doctor.  I am not giving you medical advice.  I’m not saying any one thing will treat or cure COVID.  We clear?

I’m a REPORTER.  I research and I report and I give you the full story open and honestly so YOU can decide.

With that said, I know ivermectin can potentially be extremely difficult to obtain due to the criminal censorship campaign by the mainstream media and federal government.

We’ve even had reports of the FDA colluding with USPS to seize shipments of ivermectin.

That’s why I want to update you on a change to the FLCCC Alliance I-Mask+ Prevention & Early Outpatient Treatment Protocol for COVID-19.

Their team of COVID-19 frontline physicians added an ivermectin alternative to the protocol.

The alternative is nigella sativa (black cumin seed)!

Here’s a picture of the updated protocol:

Recent research has shown promising results for nigella sativa in COVID-19 treatment protocols:

As stated in the September 2021 edition of Complementary Therapies in Medicine:


Effective treatment for Coronavirus Disease-2019 (COVID-19) is under intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and immunomodulatory activities, and has been recommended for the treatment of COVID-19. This study aimed to evaluate the efficacy of NSO treatment in patients with COVID-19.



A total of 173 patients were enrolled for RCT. The average age was 36(±11) years, and 53 % of patients were males. The control and NSO groups included 87 and 86 patients respectively. The percentage of recovered patients in NSO group (54[62 %]) was significantly higher than that in the control group (31[36 %]; p = 0.001). The mean duration to recovery was also shorter for patients receiving NSO (10.7 ± 3.2 days) compared with the control group (12.3 ± 2.8 days); p = 0.001.


NSO supplementation was associated with faster recovery of symptoms than usual care alone for patients with mild COVID-19 infection. These potential therapeutic benefits require further exploration with placebo-controlled, double-blinded studies.

PubMed listed the March 2021 study titled “Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure

Nigella sativa seed and its active compounds have been historically recognized as an effective herbal panacea that can establish a balanced inflammatory response by suppressing chronic inflammation and promoting healthy immune response. The essential oil and other preparations of N. sativa seed have substantial therapeutic outcomes against immune disturbance, autophagy dysfunction, oxidative stress, ischemia, inflammation, in several COVID-19 comorbidities such as diabetes, cardiovascular disorders, Kawasaki-like diseases, and many bacterial and viral infections. Compelling evidence in the therapeutic efficiency of N. sativa along with the recent computational findings is strongly suggestive of combating emerged COVID-19 pandemic. Also, being an available candidate in nutraceuticals, N. sativa seed oil could be immensely potential and feasible to prevent and cure COVID-19. This review was aimed at revisiting the pharmacological benefits of N. sativa seed and its active metabolites that may constitute a potential basis for developing a novel preventive and therapeutic strategy against COVID-19. Bioactive compounds of N. sativa seed, especially thymiquinone, α-hederin, and nigellidine, could be alternative and promising herbal drugs to combat COVID-19. Preclinical and clinical trials are required to delineate detailed mechanism of N. sativa’s active components and to investigate their efficacy and potency under specific pathophysiological conditions of COVID-19.

Published in November 2020, News Medical Life Sciences suggested honey and nigella sativa for COVID-19 patients:

Keeping this in mind, a team of researchers from various institutes across Pakistan, Chile, Canada, and the USA recently conducted a clinical trial to investigate the potential effectiveness of a combination of honey and Nigella sativa (HNS) in treating COVID-19 patients. Their study is published on the preprint server medRxiv* prior to the scientific peer review process*. Since previous studies show that both components of HNS have proven anti-microbial, anti-viral, anti-inflammatory, and immune-modulatory effects, the researchers wanted to assess the efficacy of HNS in fighting COVID-19.

Healing properties of honey and Nigella sativa

Honey has been reported to have beneficial effects against many viruses, including herpes simplex virus (HSV), rubella virus, Hepatitis virus, and Varicella Zoster virus. It is also effective against many multidrug-resistant bacterial strains, especially when used along with antibiotics. In addition to its immunity-boosting effects that stimulate innate as well as adaptive immune responses, honey has been shown to be beneficial in fighting upper respiratory tract infections.

Nigella sativa is a medicinal plant commonly known as Black Cumin and has been proven to have anti-viral properties against many viruses, including mouse cytomegalovirus and HCV. In vitro studies have shown that it can decrease the replication of severe acute respiratory syndrome coronavirus (SARS-CoV). Some of its components have a high affinity to many SARS-CoV-2 proteins and enzymes.

A team of Pakistan researchers released this preprint study on the effects of honey and nigella sativa against COVID-19:

RESULTS Three hundred and thirteen patients – 210 moderate and 103 severe – underwent randomization from April 30 to July 29, 2020. Among these, 107 were assigned to HNS whereas 103 to placebo for moderate cases. For severe cases, 50 were given HNS and 53 were given placebos. HNS resulted in ∼50% reduction in time taken to alleviate symptoms as compared to placebo (Moderate (4 versus 7 days), Hazard Ratio [HR]: 6.11; 95% Confidence Interval [CI]: 4.23-8.84, P<0.0001 and severe (6 versus 13 days) HR: 4.04; 95% CI, 2.46-6.64, P<0.0001). HNS also cleared the virus 4 days earlier than placebo group in moderate (6 versus 10 days, HR: 5.53; 95% CI: 3.76-8.14, P<0.0001) and severe cases (8.5 versus 12 days, HR: 4.32; 95% CI: 2.62-7.13, P<0.0001). HNS further led to a better clinical score on day 6 with normal activity resumption in 63.6% versus 10.9% among moderate cases (OR: 0.07; 95% CI: 0.03-0.13, P<0.0001) and hospital discharge in 50% versus 2.8% in severe cases (OR: 0.03; 95% CI: 0.01-0.09, P<0.0001). In severe cases, mortality rate was four-fold lower in HNS group than placebo (4% versus 18.87%, OR: 0.18; 95% CI: 0.02-0.92, P=0.029). No HNS-related adverse effects were observed.

CONCLUSION HNS significantly improved symptoms, viral clearance and mortality in COVID-19 patients. Thus, HNS represents an affordable over the counter therapy and can either be used alone or in combination with other treatments to achieve potentiating effects against COVID-19.

Just a reminder of this disclaimer:

I am not a doctor.  I am not giving you medical advice.  I’m not saying any one thing will treat or cure COVID.  We clear?

I’m a REPORTER.  I research and I report and I give you the full story open and honestly so YOU can decide.


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!